Renowned experts in virology, immunology, and drug development will help guide INTREPID's efforts to accelerate breakthrough antiviral therapies for emerging viral pandemic agents

病毒学、免疫学和药物开发领域的知名专家将帮助指导勇敢的努力，加速对新兴病毒性大流行药物的突破性抗病毒治疗

CAMBRIDGE, Mass., Oct. 22, 2024 /PRNewswire/ -- The INTREPID Alliance, a consortium of innovative biopharmaceutical companies dedicated to accelerating the development of antiviral treatments to help protect the world ahead of future pandemics, today announced the formation of its Scientific Advisory Board (SAB).

马萨诸塞州剑桥，2024年10月22日/PRNewswire/--无畏联盟（The INTREPID Alliance）是一个由创新生物制药公司组成的财团，致力于加速抗病毒治疗的发展，以帮助保护世界免受未来大流行的影响，今天宣布成立其科学咨询委员会（SAB）。

Comprising experts in infectious disease research, drug development, innovation and global public health, the SAB will work closely with INTREPID to strengthen its goals to improve pandemic preparedness, and to accelerate the development of potentially life-saving treatments for emerging viral pandemic agents..

SAB由传染病研究、药物开发、创新和全球公共卫生领域的专家组成，将与无畏密切合作，加强其改进大流行防范的目标，并加速为新兴病毒性大流行因子开发潜在的挽救生命的治疗方法。。

Specifically, the SAB will provide expert guidance to INTREPID on antiviral research priorities, advising on emerging trends, program strategy, and key scientific issues. It will also interpret landscape data, and help shape long-term strategies to enhance pandemic preparedness.

具体而言，SAB将为勇敢者提供抗病毒研究优先事项的专家指导，就新兴趋势，计划策略和关键科学问题提供建议。它还将解释景观数据，并帮助制定长期战略，以加强大流行防范。

Ruxandra Draghia-Akli, M.D., Ph.D., who was announced as the inaugural chair of the SAB earlier this year, brings to this advisory group a proven track record of driving the discovery, development, and commercialization of pioneering products that advance public health. She is the future Executive Vice President and Head of Research & Development at Novavax where she will be responsible for the company's expanded R&D strategy.

Ruxandra Draghia Akli，医学博士，博士，今年早些时候被宣布为SAB的首任主席，为这个咨询小组带来了一个行之有效的记录，推动了开拓性产品的发现，开发和商业化，促进了公共卫生。她将担任Novavax未来的执行副总裁兼研发主管，负责公司扩大的研发战略。

In her previous role at Johnson & Johnson, Dr. Draghia-Akli built a leading Global Public Health R&D organization, delivering groundbreaking innovation to address climate-related, emerging, and entrenched health threats, such as dengue, coronaviruses, antimicrobial resistance, tuberculosis, and leprosy.

Draghia Akli博士在强生公司任职期间，建立了一个领先的全球公共卫生研发组织，为应对登革热、冠状病毒、抗菌素耐药性、结核病和麻风病等与气候相关的、新兴的和根深蒂固的健康威胁提供了开创性的创新。

Known for fostering impactful partnerships, she has also led key initiatives such as European Commission's Health Research and Innovation Program, including the Innovative Medicines Initiative (IMI), and co-chaired the ACTIV Therapeutics Clinical Working Group of the U.S. National Institutes of Health (NIH) during the COVID-19 pandemic..

以培养有影响力的伙伴关系而闻名，她还领导了欧盟委员会的健康研究和创新计划等关键举措，包括创新药物倡议（IMI），并在新型冠状病毒大流行期间共同主持了美国国立卫生研究院（NIH）的ACTIV治疗临床工作组。。

'I am honored to serve as the inaugural chair of the INTREPID Alliance Scientific Advisory Board,' said Dr. Draghia-Akli. 'Antiviral treatments are a fundamental part of the world's collective defense against new and known viruses – but to achieve this defense, we must catalyze efforts to fill current pipeline gaps.

抗病毒治疗是全球共同防御新病毒和已知病毒的基本组成部分，但要实现这种防御，我们必须推动填补目前管道缺口的努力。

Together with INTREPID members, collaborators and my esteemed SAB colleagues, I look forward to helping shape a stronger pipeline for antiviral research, in order to ensure better preparedness against endemic and pandemic threats and deliver the next generation of life-saving medicines.'.

我期待着与勇敢的成员、合作者和我尊敬的SAB同事一起，帮助建立一个更强大的抗病毒研究渠道，以确保更好地应对地方性和大流行威胁，并提供下一代救生药物。”。

The SAB members include:

SAB成员包括：

Constance Benson, M.D., Professor of Medicine and Global Public Health, Division of Infectious Diseases and Global Public Health, University of California San Diego

康斯坦斯·本森（Constance Benson），医学博士，加利福尼亚大学圣地亚哥分校传染病与全球公共卫生系医学与全球公共卫生教授

Dr. Benson is an internationally-recognized clinical and translational researcher and clinician working in the fields of HIV and tuberculosis since 1984 – and more recently, SARS-CoV-2. She is a Professor of Medicine and Global Public Health, Senior Attending Physician, the Co-Director of the Antiviral Research Center, and the Principal Investigator for the HIV Collaborative Clinical Trials Unit within the Division of Infectious Diseases and Global Public Health at University of California, San Diego (UCSD).

Benson博士是国际公认的临床和转化研究人员和临床医生，自1984年以来一直在艾滋病毒和结核病领域工作，最近又是SARS-CoV-2。她是医学和全球公共卫生教授、高级主治医师、抗病毒研究中心联合主任，也是加州大学圣地亚哥分校传染病与全球公共卫生部HIV合作临床试验部门的首席研究员。

From 2003 - 2010 Dr. Benson led the NIH/NIAID AIDS Clinical Trials Group (ACTG) Network. Her current major areas of research interest include Mycobacterium tuberculosis, other non-tuberculous mycobacterial diseases, new antiretroviral drug development, and the treatment of emerging infectious diseases in resource-limited settings..

从2003年到2010年，Benson博士领导了NIH/NIAID艾滋病临床试验小组（ACTG）网络。她目前的主要研究兴趣领域包括结核分枝杆菌，其他非结核分枝杆菌疾病，新型抗逆转录病毒药物开发以及在资源有限的环境中治疗新发传染病。。

Kelly Chibale, Ph.D., Neville Isdell Chair in African-centric Drug Discovery and Development, University of Cape Town

凯利·奇贝尔（Kelly Chibale）博士，开普敦大学以非洲为中心的药物发现与开发的Neville Isdell主席

Dr. Chibale is a full Professor of Organic Chemistry at the University of Cape Town (UCT), where he holds the Neville Isdell Chair in African-centric Drug Discovery & Development.  He is also a Schmidt Sciences AI2050 Senior Fellow, and the Founder and Director of the UCT Holistic Drug Discovery and Development (H3D) Centre and H3D Foundation.

Chibale博士是开普敦大学（UCT）有机化学的全职教授，他担任以非洲为中心的药物发现与开发的Neville Isdell主席。他还是施密特科学AI2050高级研究员，UCT整体药物发现与开发（H3D）中心和H3D基金会的创始人和主任。

His research interests are in infectious disease drug discovery and the development of tools and models to contribute to improving treatment outcomes in people of African descent. In recognition of his pioneering work, Dr. Chibale was named one of Fortune magazine's 50 World's Greatest Leaders in 2018, among many other esteemed awards and honors he's received.

他的研究兴趣是传染病药物的发现以及工具和模型的开发，以帮助改善非洲人后裔的治疗效果。为了表彰他的开创性工作，奇贝尔博士被《财富》杂志评为2018年全球50位最伟大的领导者之一，并获得了许多其他受人尊敬的奖项和荣誉。

He currently serves as Editor-In-Chief of the American Chemical Society (ACS)'s ACS Medicinal Chemistry Letters..

他目前担任美国化学学会（ACS）的ACS药物化学快报的主编。。

Barry Clinch, Ph.D., Consultant and Director, Pottersheath Associates Ltd.

Barry Clinch博士，Pottersheath Associates Ltd.顾问兼董事。

Dr. Clinch is an independent consultant specializing in all aspects of clinical development strategy for pharma and biotech clients in the infectious disease space. With 25 years of experience in the biopharmaceutical industry, he previously served as Global Head of Infectious Disease at Roche, where he led clinical science activities to support the development, filing and life-cycle management of high-profile influenza antivirals.

克林奇博士是一名独立顾问，专门从事传染病领域制药和生物技术客户临床发展战略的各个方面。凭借25年的生物制药行业经验，他曾担任罗氏公司传染病全球负责人，领导临床科学活动，支持备受关注的流感抗病毒药物的开发，归档和生命周期管理。

He also worked closely with early development on therapeutic monoclonal antibodies (mAbs) for influenza and novel antibiotics for gram negative infections. During the COVID-19 pandemic, Dr. Clinch played a key role in shaping Roche's strategic response and expanded the infectious disease team to support global filing activities for mAbs and global clinical development of a small molecule direct acting antiviral, in partnership with Regeneron and Atea respectively..

他还与流感治疗性单克隆抗体（mAb）和革兰氏阴性感染新型抗生素的早期开发密切合作。在新型冠状病毒肺炎大流行期间，克林奇博士在塑造罗氏的战略反应方面发挥了关键作用，并扩大了传染病团队，分别与Regeneron和Atea合作，支持单克隆抗体的全球申报活动和小分子直接作用抗病毒药物的全球临床开发。。

Ken Duncan, Ph.D., Deputy Director, Discovery and Translational Sciences, Gates Foundation

肯·邓肯博士，盖茨基金会发现与转化科学副主任

Dr. Duncan joined the Gates Foundation in 2007, where he leads the drug discovery program in tuberculosis (TB), malaria, antivirals and contraception. In this role, he established the TB Drug Accelerator to facilitate collaboration across industry, academia, and non-profit teams to speed up drug discovery research.

邓肯博士于2007年加入盖茨基金会，领导结核病、疟疾、抗病毒药物和避孕药物发现项目。在担任这一职务时，他建立了结核病药物加速器，以促进行业，学术界和非营利团队之间的合作，以加速药物发现研究。

He also played a major role in launching the Global Health Drug Discovery Institute in Beijing, China. Dr. Duncan currently serves on the Selection Committee of the Global Health Innovative Technology Fund in Japan and is a member of the Governing Board of the Tres Cantos Open Lab Foundation in Spain.

他还为在中国北京成立全球健康药物发现研究所发挥了重要作用。邓肯博士目前在日本全球健康创新技术基金选拔委员会任职，是西班牙Tres Cantos开放实验室基金会理事会成员。

Before joining the Foundation, Ken spent 16 years at GSK, most recently as Director, Diseases of the Developing World..

在加入基金会之前，肯在葛兰素史克（GSK）工作了16年，最近一次是担任发展中国家疾病总监。。

Daria Hazuda, Ph.D., Head of Infectious Disease and Vaccine Research, Generate:Biomedicines

Daria Hazuda博士，传染病和疫苗研究负责人，Generate：生物医学

Dr. Hazuda is a renowned expert in infectious disease and vaccine research, currently serving as Head of Infectious Disease and Vaccine Research at Generate:Biomedicines. Before joining Generate:Biomedicines, she spent 30 years at Merck where she held positions of increasing responsibility managing cross-functional research resulting in multiple approved drugs and vaccines including antivirals for HIV, hepatitis C, and cytomegalovirus, as well as antibacterials.

Hazuda博士是传染病和疫苗研究领域的著名专家，目前担任Generate：Biomedicines传染病和疫苗研究负责人。在加入Generate：Biomedicines之前，她在默克公司工作了30年，负责管理跨功能研究，产生了多种批准的药物和疫苗，包括艾滋病毒，丙型肝炎和巨细胞病毒的抗病毒药物以及抗菌药物。

Notably, Dr. Hazuda led research efforts that identified the first-in-class HIV integrase inhibitor, which won the 2008 Prix Galien award. Dr. Hazuda retired from Merck as the Vice President of Infectious Disease and Vaccines and Chief Scientific Officer of the Cambridge Research site..

值得注意的是，哈祖达博士领导的研究工作确定了第一个一流的HIV整合酶抑制剂，该抑制剂获得了2008年加利恩奖。Hazuda博士从默克公司退休，担任传染病和疫苗副总裁兼剑桥研究中心首席科学官。。

Johan Neyts, Ph.D., Full Professor of Virology, University of Leuven (KU Leuven)

约翰·奈茨博士，鲁汶大学病毒学教授

Dr. Neyts is a full Professor of Virology at the University of Leuven (KU Leuven), Belgium where he teaches at the medical and dental schools. He is an expert in developing antiviral strategies and drugs against emerging and neglected viral infections, including dengue, Chikungunya and other alphaviruses, enteroviruses, noroviruses, hepatitis D and E viruses, rabies and coronaviruses.

内茨博士是比利时鲁汶大学（KU-Leuven）的病毒学全职教授，他在医学院和牙科学院任教。他是开发抗病毒策略和药物以对抗新出现和被忽视的病毒感染的专家，包括登革热、基孔肯雅热和其他α病毒、肠道病毒、诺如病毒、丁型和戊型肝炎病毒、狂犬病和冠状病毒。

Together with the Centre for Drug Design & Development, his lab developed a candidate pan-serotype dengue inhibitor. He also co-developed a Phase 1 vaccine platform and is the founder of the KU Leuven spin-off AstriVax. Dr. Neyts is a past president of the International Society for Antiviral Research and leads the Belgian VirusBank platform, a €20 million investment of the Belgian Federal Government in epidemic/pandemic preparedness, which he also co-founded..

与药物设计与开发中心一起，他的实验室开发了一种候选的泛血清型登革热抑制剂。他还共同开发了一个第一阶段疫苗平台，并且是KU-Leuven分拆AstriVax的创始人。Neyts博士是国际抗病毒研究学会（International Society for Antiviral Research）的前任主席，并领导比利时病毒库平台（Belgian VirusBank platform），这是比利时联邦政府在流行病/大流行防范方面的2000万欧元投资，也是他共同创建的。。

ABOUT THE INTREPID ALLIANCE

关于无畏联盟

The INTREPID Alliance aims to accelerate the development of new treatments for emerging viral pandemic agents through facilitating early science and R&D, policy and advocacy, and stakeholder engagement. Led by a not-for-profit consortium of innovative biopharmaceutical companies and working with the public, private and not-for-profit sectors, INTREPID works to bridge key gaps and unmet needs to ensure delivery of antiviral solutions to viral pathogens with the greatest pandemic potential..

无畏联盟旨在通过促进早期科学和研发、政策和宣传以及利益相关者的参与，加速开发针对新兴病毒性大流行病原体的新疗法。在创新生物制药公司的非营利性财团的领导下，与公共、私营和非营利性部门合作，无畏努力弥合关键差距和未满足的需求，以确保为具有最大流行潜力的病毒病原体提供抗病毒解决方案。。

INTREPID was launched in March 2023 at a high-level summit bringing together more than 100 thought leaders in virology and global health. For a read-out from the summit and additional information, visit www.intrepidalliance.org.

INTREPID于2023年3月在一次高级别峰会上推出，汇集了100多名病毒学和全球卫生领域的思想领袖。有关峰会的宣读和其他信息，请访问www.intrepidalliance.org。

SOURCE INTREPID Alliance

来源无畏联盟

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

想在PRNEWSWIRE上发布贵公司的新闻。COM？

440k+

44万+

Newsrooms &

新闻编辑室&

Influencers

影响者

9k+

9千+

Digital Media

数字媒体

Outlets

出口

270k+

27万+

Journalists

记者

Opted In

选择加入

GET STARTED

快速入门